Back to news

Why Rapport Therapeutics (RAPP) Stock Is Up Today

Investivoq PriceTracker

Rapport Therapeutics (RAPP) is up 4.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is Rapport’s October 20, 2026 announcement of positive topline Phase 2 data for RAP-219 in bipolar mania. Investors appear to be reacting to the trial meeting its primary endpoint, showing statistical significance on a secondary measure, and giving the company a clearer path toward Phase 3 development.

Details:

  • Rapport said RAP-219 met the primary endpoint in its Phase 2 bipolar mania trial, with a 3.1-point placebo-adjusted improvement on the Young Mania Rating Scale at Week 3.
  • The company also reported a statistically significant benefit on a key secondary endpoint measuring mania severity, which can strengthen confidence in the dataset.
  • Management said the results establish clinical proof-of-concept in bipolar mania and support plans to begin Phase 3 trials in the second half of 2027, with an FDA meeting targeted for the first quarter of 2027.
  • The safety profile also appears to have helped sentiment, as the company described RAP-219 as well tolerated, with adverse events generally balanced versus placebo and no severe treatment-emergent adverse events or serious adverse events reported.

    • Sources:

    SEC, GlobeNewswire, Rapport Therapeutics

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $RAPP Insider Trading Activity

    RAPP Insider Trades

    $RAPP insiders have traded $RAPP stock on the open market 28 times in the past 6 months. Of those trades, 0 have been purchases and 28 have been sales.

    Here’s a breakdown of recent trading of $RAPP stock by insiders over the last 6 months:

    • ROCK VENTURES V, L.P. THIRD has made 0 purchases and 2 sales selling 152,190 shares for an estimated $6,121,075.
    • ABRAHAM CEESAY (Chief Executive Officer) has made 0 purchases and 19 sales selling 104,002 shares for an estimated $4,724,365.
    • CHERYL GAULT (Chief Operating Officer) has made 0 purchases and 6 sales selling 20,000 shares for an estimated $747,654.
    • KRISHNASWAMY YELESWARAM (Chief Development Officer) sold 404 shares for an estimated $20,159

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive RAPP Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $RAPP Hedge Fund Activity

    We have seen 77 institutional investors add shares of $RAPP stock to their portfolio, and 59 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • TRV GP V, LLC removed 854,708 shares (-12.0%) from their portfolio in Q2 2026, for an estimated $35,615,682
    • VESTAL POINT CAPITAL, LP removed 706,229 shares (-49.2%) from their portfolio in Q2 2026, for an estimated $29,428,562
    • CORMORANT ASSET MANAGEMENT, LP removed 300,000 shares (-10.1%) from their portfolio in Q2 2026, for an estimated $12,501,000
    • UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 274,784 shares (-29.9%) from their portfolio in Q2 2026, for an estimated $11,450,249
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 246,815 shares (+inf%) to their portfolio in Q2 2026, for an estimated $10,284,781
    • ALGERT GLOBAL LLC added 223,822 shares (+inf%) to their portfolio in Q2 2026, for an estimated $9,326,662
    • BLACKROCK, INC. added 193,831 shares (+7.7%) to their portfolio in Q2 2026, for an estimated $8,076,937

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $RAPP Analyst Ratings

    Wall Street analysts have issued reports on $RAPP in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • BTIG issued a "Buy" rating on 05/08/2026

    To track analyst ratings and price targets for $RAPP, check out Investivoq's $RAPP forecast page.

    $RAPP Price Targets

    Multiple analysts have issued price targets for $RAPP recently. We have seen 3 analysts offer price targets for $RAPP in the last 6 months, with a median target of $56.0.

    Here are some recent targets:

    • Marc Goodman from Leerink Partners set a target price of $52.0 on 06/24/2026
    • Kambiz Yazdi from BTIG set a target price of $65.0 on 05/21/2026
    • Danielle Brill from Truist Securities set a target price of $56.0 on 05/19/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.